About AVT
Browse Articles
Customer Services


SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection

Elise J Smolders, Lindsey HM te Brake, David M Burger

Corresponding author name: Elise J Smolders
Corresponding author e-mail: Elise.Smolders@radboudumc.nl

Citation: Antiviral Therapy 2020; 25:345-347
doi: 10.3851/IMP3365

Date accepted: 16 June 2020
Date published online: 26 June 2020


Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2, lopinavir/ritonavir was selected for treatment. The recent publication of Cao et al. in the New England Journal of Medicine showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care. This raised the question of whether in retrospect we could have known this. The aim of this paper is to gather all the available evidence and to comprehensively discuss this issue.


Copyright © 2021 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.